Can a scan replace the needle? ultrasound and MRI put to the test against liver biopsy for fatty liver disease

This study investigates whether non-invasive imaging techniques—ultrasound and MRI—can accurately diagnose non-alcoholic steatohepatitis (NASH) and liver fibrosis in people with fatty liver disease. Currently, a liver biopsy is the gold standard, but it is invasive and carries risks. The trial enrolls patients who already need a biopsy and compares imaging results to the biopsy findings, aiming for at least 90% accuracy. If successful, these imaging methods could offer a safer, more practical way to identify patients who might benefit from future NASH treatments.